Key Insights

Highlights

Success Rate

82% trial completion

Published Results

27 trials with published results (11%)

Research Maturity

75 completed trials (31% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.1%

17 terminated out of 241 trials

Success Rate

81.5%

-5.0% vs benchmark

Late-Stage Pipeline

15%

37 trials in Phase 3/4

Results Transparency

36%

27 of 75 completed with results

Key Signals

27 with results82% success17 terminated

Data Visualizations

Phase Distribution

155Total
Not Applicable (73)
Early P 1 (4)
P 1 (9)
P 2 (32)
P 3 (11)
P 4 (26)

Trial Status

Completed75
Recruiting62
Unknown40
Not Yet Recruiting21
Terminated17
Active Not Recruiting14

Trial Success Rate

81.5%

Benchmark: 86.5%

Based on 75 completed trials

Clinical Trials (241)

Showing 20 of 20 trials
NCT05064709Not ApplicableRecruiting

Assessment of CCM in HF With Higher Ejection Fraction

NCT07037459Phase 3RecruitingPrimary

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT05093959Phase 2CompletedPrimary

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

NCT07554638Phase 4Not Yet Recruiting

Incretin Therapies in Obesity-related HFpEF

NCT05752760Not ApplicableCompleted

Pilot Study Lp299v Supplementation in Chronic Heart Failure

NCT06652763RecruitingPrimary

Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction

NCT07083011Phase 2RecruitingPrimary

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT05839730Not ApplicableRecruitingPrimary

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

NCT02835638Completed

Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV

NCT05795400Not ApplicableCompleted

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

NCT06312748Phase 1RecruitingPrimary

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

NCT07401771RecruitingPrimary

Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction

NCT04998877Active Not RecruitingPrimary

Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients

NCT05138575Phase 2RecruitingPrimary

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

NCT04862273Completed

CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis

NCT05719714Phase 1Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

NCT05873634Recruiting

HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

NCT06517186Recruiting

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

NCT05393362Not ApplicableCompletedPrimary

Effectiveness of a Cardiac Rehabilitation Program in Elderly Patients With Heart Failure.

NCT06616974Phase 2Recruiting

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

Scroll to load more

Research Network

Activity Timeline